Ocugen price to book ratio OCGN

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 71.7×; Jul 2026
10-year median: 6.4×
10-year range: 1.3× to 170×
Peer median: 5.0×

Ocugen's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Jul 2026, at 71.7×.

On the days it had one over the last ten years, its median was 6.4×, from 1.3× in Oct 2023 to 170× in Oct 2025.

Price to book ratio over time

median 6.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	71.7×	70.6×	161×
2025	125×	4.7×	170×
2024	6.1×	2.2×	22.1×
2023	2.5×	1.3×	3.0×
2022	3.0×	2.8×	7.9×
2021	8.5×	8.5×	123×
2020	20.6×	1.3×	20.6×
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	59.7×	2.7×	62.8×
2016	6.6×	0.8×	9.3×
2015	1.3×	1.1×	2.2×

Against its peers

Companies in Biotechnology nearest Ocugen's size, closest first, today.

Company	Price to book ratio
OCGNOcugen	n/m
PLXProtalix BioTherapeutics	2.9×
MGTXMeiraGTx	4.1×
VCELVericel	5.9×
ADMAAdma Biologics	5.9×
Peer median	5.0×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Ocugen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.